Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 17, 2009

EMBL Licenses Tripos' Software to Advance Drug Discovery

EMBL Licenses Tripos' Software to Advance Drug Discovery

EMBL to advance drug discovery research with Tropos' software

  • The European Molecular Biology Laboratory (EMBL) signed an agreement to license Tripos' Themis and Surflex-Dock software to advance its drug discovery efforts within chemical biology.

    The software will be used to enable small molecule development among research groups in the Chemical Biology Core Facility, a three-way collaboration between the EMBL, the German Cancer Research Center, and the University of Heidelberg.

    The EMBL says that in studies to assess Surflex-Dock, the software yielded promising compound candidates for testing in about two days.

    It docked five million structures of the research institute's virtual database of commercially available compounds into a binding site of a project's receptor structure.

    Additionally, in the first experiments with Themis, the software provided new chemical ideas that would contribute to drug discovery projects, adds Joe Lewis, Ph.D, head of the facility.ADNFCR-2184-ID-19031149-ADNFCR



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »